Trial Profile
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs MEDI 6469 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2022 Status changed from active, no longer recruiting to discontinued since study drug expired and access to additional supply ended.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2015 New trial record